Amgen’s Bevacizumab Biosimilar Is Alone On Australia’s PBS
As Celltrion’s Remsima SC Is Also Added To Pharmaceutical Benefits Scheme
Executive Summary
US-based giant Amgen has seen its Mvasi biosimilar become the sole bevacizumab product listed on Australia’s Pharmaceutical Benefits Scheme.
You may also be interested in...
Pfizer Bids To Stop Samsung Bioepis’ Etanercept In Australia
Enbrel (etanercept) originator Pfizer has filed suit in Australia over the sale of Samsung Bioepis’ rival Brenzys biosimilar. It alleges that it has “suffered, and will continue to suffer, substantial loss and damage.”
Celltrion Eyes Remsima SC Launches In Canada And Australia
While Celltrion has delivered an unimpressive first quarter of 2021, the company has pointed to plans to launch high-margin products in new markets. The Korean firm said that it was looking to launch its subcutaneous Remsima SC infliximab formulation in Canada and Australia in 2021, while it is also aiming to launch its Yuflyma (adalimumab) in more than 70% of the EU adalimumab market.
Australia Extends Biosimilar Education Efforts
Australia’s government has agreed to extend a successful biosimilar education initiative led by the local GBMA industry association.